ZymoGenetics Claims Competitor's Product Poses Serious Patient Safety Issue
This article was originally published in The Pink Sheet Daily
Executive Summary
As it tries to build market share for Recothrom, ZymoGenetics files Citizen's Petition asking FDA to remove its top competitor from the market.
You may also be interested in...
FDA Challenges ZymoGenetics' Safety Claims
Agency takes issue with part of the better-than-bovine thrombin boast.
ZymoGenetics Will Ship Topical Hemostat Recothrom In Two Weeks
Company will price the recombinant, plasma-free thrombin at a 20 percent premium over competitor King's bovine-derived Thrombin JMI.
ZymoGenetics Allies With Bayer To Blitz U.S. Hospital Market With rhThrombin
Bayer receives ex-U.S. rights to develop and market the recombinant thrombin therapy.